Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)
China
· Delayed Price · Currency is CNY 56.68
-1.52 (-2.61%)
Mar 9, 2026, 3:00 PM CST
SHA:688336 Revenue
In the year 2025, Sunshine Guojian Pharmaceutical (Shanghai) had annual revenue of 4.20B CNY with 251.81% growth. Sunshine Guojian Pharmaceutical (Shanghai) had revenue of 3.08B in the quarter ending December 31, 2025, with 1,113.05% growth.
Revenue
4.20B
Revenue Growth
+251.81%
P/S Ratio
8.34
Revenue / Employee
4.22M
Employees
1,023
Market Cap
35.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.20B | 3.01B | 251.81% |
| Dec 31, 2024 | 1.19B | 179.53M | 17.70% |
| Dec 31, 2023 | 1.01B | 188.54M | 22.84% |
| Dec 31, 2022 | 825.49M | -103.32M | -11.12% |
| Dec 31, 2021 | 928.81M | 273.80M | 41.80% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Asymchem Laboratories (Tianjin) | 6.29B |
| Chongqing Zhifei Biological Products | 10.91B |
| Hebei Changshan Biochemical Pharmaceutical | 928.01M |
| Beijing Tiantan Biological Products | 6.42B |
| Shanghai RAAS Blood Products | 7.95B |
| Shanghai Allist Pharmaceuticals | 5.17B |
| Xiamen Amoytop Biotech | 3.70B |
| Pharmaron Beijing | 13.54B |